Drugs / KIO-100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03769454 | Nov 2018 → Sep 2021 | keratoconjunctivitis | Panoptes Pharma GmbH | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03634475 | Jan 2017 → Nov 2018 | uveitis | Panoptes Pharma GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06825702 | May 2025 → Nov 2026 expected | macular retinal edema | Kiora Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-04-26 | Kiora Pharmaceuticals, Inc. | Results Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects kiorapharma.com ↗
The results of this clinical trial demonstrate that an intravitreal KIO-100 formulation is safe and has the potential to be further developed as a new intraocular therapy for autoimmune uveitis and CME. |
| 2022-10-17 | Kiora Pharmaceuticals, Inc. | Results Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease kiorapharma.com ↗
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from a Phase 1 study of KIO-100 (formerly PP-001) demonstrate its potential as a treatment for non-infectious uveitis, an ophthalmic inflammatory disease. |
All press releases naming this drug 7 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KIO-100 | “KIO-104 is an ophthalmic formulation for IVT injection of the active pharmaceutical ingredient (API) KIO-100, a novel, non-steroidal, small molecule inhibitor of dihydroorotate...” NCT06825702 ↗1“A new small molecule DHODH-inhibitor [KIO-100 (PP-001)]” PMID 36325389 ↗ Oct 2022 |
| Known as | PP-001 | “A new small molecule DHODH-inhibitor [KIO-100 (PP-001)]” PMID 36325389 ↗ Oct 2022 |
| Action | Inhibit | “PP-001 is a novel small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH)” NCT03769454 ↗ |
| Modality | Small molecule | “PP-001 is a novel, anti-inflammatory small molecule” NCT03769454 ↗ |
| Route | Topical | “PP-001 eye drops” NCT03769454 ↗ |
| Target | DHODH | “PP-001 is a novel small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH)” NCT03769454 ↗ |